Zefia Siegfried

Doctor of Medicine,  Toronto General - University Health Network 

Location: India

Consulting Services

Hospital-Pharmacy-Insurance Legal Support Scientific Writing Grant Submission

Areas Of Interest

MAP Kinase Kinase 2 Goldenhar Disease Nutrition Guideline Tyrosine Kinase, Bruton's Tocopherol Bayer Allylbenzene Derivatives Missense Mutations Popliteal Veins cao, Gan Izoptin Infection, Clostridium sordellii Antigen, CD135 Utilitarianism Joint, Carpal D-Transferase, GSTP1 Glutathione Gene, rev Angiokeratoma Corporis Diffusum Karyopherin-beta Junction, Neuronal Gap Fields, Supplementary Eye Nerves, Hypoglossal Episode, Patient Care Tumors, Medullary Microscopy, Hand-Held Serum-Free Culture Media Biliary Sphincterotomy, Endoscopic Coretal Receptors for Activated C Kinase Carotid Arteries, Common beta-D-Glucopyranosyl-Isomer Paromomycin Euphorbia hirta Lactate dehydrogenase-elevating virus Drug Rehabilitation Centers Karyotyping Mean Platelet Volume Acarus Nu Gemfibrozil

Professional Narrative

Dr. Zefia Siegfried was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Siegfried has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.

Employment

Senior Director, Harvard Med 2011
Assistant Professor, Harvard Med 1998

Education

Master of Science in physician assistant, Yale School of Medicine 1987
Director Medicine, Weill Medical College 2006

Referees

Publications

Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326-1335. doi: 10.1021/acs.nanolett.6b03329. Epub 2016 Dec 5. PMID: 28273716; PMCID: PMC5523404.

Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326-1335. doi: 10.1021/acs.nanolett.6b03329. Epub 2016 Dec 5. PMID: 28273716; PMCID: PMC5523404.

Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326-1335. doi: 10.1021/acs.nanolett.6b03329. Epub 2016 Dec 5. PMID: 28273716; PMCID: PMC5523404.

Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M, Graham DB, Jhunjhunwala S, Heidenreich M, Xavier RJ, Langer R, Anderson DG, Hacohen N, Regev A, Feng G, Sharp PA, Zhang F. CRISPR- Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014 Oct 9;159(2):440-55. doi: 10.1016/j.cell.2014.09.014. Epub 2014 Sep 25. PMID: 25263330; PMCID: PMC4265475.

Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :

Languages

Language Proficiency :

Translation Services :

Serving Millions of physicians and biomedical scientists in Industry and academia.

Site
Services
Follow Us
Contact Us
  • support@scienceandminds.com

Copyright © 2025 Trialect Inc. All rights reserved. | v2023.06.17.02